Is there an optimal time for catheterization in NSTE-ACS patients with renal failure? Insights from the ABOARD Study (ABOARD: Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Ran). 


Aim: Whether timing of catheterization (immediate versus delayed intervention) in high risk ACS has an impact on outcome in patients with RF is not known.

Methods: In the randomized ABOARD study we showed that in patients with NSTE-ACS, a "primary PCI" strategy compared with a strategy of intervention deferred to the next working day did not result in a difference of clinical outcome. We compared these two strategies according to the renal status at 1-month follow-up. Severe RF was defined by a Creatinin Clearance (CrCl) <60 ml/min. Severe RF was defined by a Creatinin Clearance (CrCl) <60 ml/min.

Results: Eight (2.3%) patients had severe RF, 67 (19.4%) moderate RF and 270 (78.3%) no RF. Baseline characteristics were well matched except for a lower multivessel disease rate in the "primary PCI" strategy group (52% vs 85%, p=0.008) in the moderate RF group. Patients received intense antplatelet therapy with a mean 660 mg (±268) clopidogrel loading dose followed by a 111 mg (±40) maintenance dose, while 99% of the PCI patients received abciximab. LMWH were used in 68% of patients and radial approach was predominant (84%). The mean peak of troponin did not differ according to the revascularization strategy whatever the renal function. Recurrent ischemia was however significantly more frequent in the moderate RF group undergoing deferred catheterization in comparison with a primary PCI strategy (33.3% vs 8.8%, p=0.014). Major bleeding complications were similar whatever the strategy in the different renal function groups.

Conclusion: Although renal failure is associated with more ischemic complications, the timing of intervention appears to have no impact on outcome of these patients. Thus, the primary results of the ABOARD study apply also to renal failure patients.
dynamic parameters (heart rate, blood pressure, grade 3 or 4 Killip, left ventricular ejection fraction (LVEF)). In group 1, predictive factors of mortality were: age, three- vessel or left main coronary artery disease, blood pressure, grade 3 or 4 Killip and LVEF.

Conclusion: Despite recent improvement in the management of STEMI, incidence of patients requiring CAD for CS is still high, and mortality elevated.

(voir tableau page précédente)

331

Effect of acute hypoxia on left ventricular twist assessed by speckle tracking imaging

Chantal Dedobbeleer (1), Guel Deboeck (2), Michel Lamotte (2), Robert Naeije (3), Philippe Unger (1)

(1) Hôpital Erasme, Cardiologie, Bruxelles, Belgique - (2) Hôpital Erasme, Bruxelles, Belgique - (3) Hôpital Erasme, Physiopathologie, Bruxelles, Belgique

Background: The impact of hypoxia on left ventricular (LV) myocardial contractility remains debated. Objectives: We hypothesized that acute hypoxia in healthy people increases LV twist as a consequence of the cardiovascular adaptation to stress (increased sympathetic nerve activity). Because hypoxia increases heart rate, we aimed to control for this change by studying the same subjects under atropine during normoxia.

Methods: We studied 21 subjects (mean age: 27 ± 7 years) without medical history. Echocardiography was performed in normoxia and after 30 minutes of hypoxia (12% FiO2). Short axis basal and apical views were analyzed using speckle tracking software. LV twist was defined as the net difference between the apical and basal rotation. The effect of atropine on LV twist was tested in the same subjects under normoxia.

Results: As expected, hypoxic breathing decreased arterial saturation in oxygen below 80% (table). Peak LV twist increased, as did heart rate, LV ejection fraction (LVEF) and systolic mitral annular velocity. Despite a decrease in mitral E/A ratio, early diastolic LV untwisting (at 5%, 10% and 15% of diastole) was not significantly modified under hypoxia. Atropine did not alter peak systolic twist (8.9 ± 3.1° versus 10.1 ± 2.6°; p=0.09), without and with atropine, respectively, despite an increase in heart rate (from 64 ± 11 to 77 ± 11 beats/min; p=0.0001).

Conclusions: Acute hypoxia increases LV twist as well as other parameters of LV contractility. This change in LV twist does not result from the chronotropic effect of hypoxia.

Values are means (SD)

<table>
<thead>
<tr>
<th>Normoxia</th>
<th>Hypoxia</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SaO2 (%)</td>
<td>97 (1.3)</td>
<td>76 (7.8)</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>64 (11)</td>
<td>70 (9)</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>65 (5)</td>
<td>68 (7)</td>
</tr>
<tr>
<td>Systolic mitral annular velocity (cm/s)</td>
<td>8.0 (1.1)</td>
<td>8.7 (1.4)</td>
</tr>
<tr>
<td>E/A</td>
<td>2.1 (0.6)</td>
<td>1.8 (0.4)</td>
</tr>
<tr>
<td>Peak LV twist (°)</td>
<td>8.9 (3.1)</td>
<td>11.1(2.8)</td>
</tr>
</tbody>
</table>

332

Predictors and prognostic value of contrast-induced nephropathy in patients undergoing primary angioplasty

Antonio Gaspar, Joao Costa, Vitor Ramos, Silvia Ribeiro, Catarina Vieira, Sérgio Nabeis, Sergia Rocha, Pedro Azevedo, Miguel Pereira, Alberto Salgado, Adelino Correia

Hospital de Braga, Cardiologie, Braga, Portugal

Purpose: Contrast-induced nephropathy (CIN) after coronary angiography has been associated to increased morbidity and mortality. Patients submitted to primary angioplasty seem to be at higher risk for CIN development, owing in part to hemodynamic status. We sought to determine the prevalence, predictors and prognostic value of CIN occurrence after primary angioplasty.

Methods: A total of 141 patients consecutively submitted to primary angioplasty and admitted to our coronary unit were reviewed. CIN was defined as impairment of renal function occurring within 48 hours after administration of contrast media and manifested by an absolute increase in the serum creatinine level of at least 0.5 mg/dl or by a relative increase of at least 25% over the baseline value (in the absence of another cause). The primary end points were in-hospital and six-month mortality.

Results: CIN developed in 18.4% of the patients (n=26). Patients with CIN were older (68 ± 13 vs 61 ± 13 years; p <0.05) and more often had diabetes mellitus (38.5% vs 15.7%; p <0.05). Although statistical significance was not reached, there was a trend for higher prevalence of hypertension (61.5% vs 42.6%; p=0.09), female gender (30.8% vs 18.3%; p=0.18) and Killip class higher than one at admission (26.9% vs 16.3%; p=0.1) among patients with CIN. Patients with CIN had an higher mean time from symptoms to reperfusion (304 ± 192 vs 397 ± 206 minutes; p <0.04). By multivariate analysis, independent correlates of CIN were older age (OR=1.04; 95%CI=1.01 – 1.08) and diabetes mellitus (OR=2.99; 95%CI=1.08 – 8.3). Patients with CIN had higher in-hospital (19.2% vs 0.9%; p <0.05) and 6-month mortality (28.6% vs 4.9%; p <0.05).

Conclusions: CIN was a frequent complication of primary angioplasty (18.4% of the patients). Independent predictors of CIN after primary angioplasty were older age and diabetes mellitus. Patients with CIN had a worse prognosis, both during in-hospital stay and at 6 months.

333

Use of recombinant factor VIIa (NovoSeven) in patients treated with fondaparinux for ongoing life-threatening bleeding

François Schiele (1), Paul Luporsi (1), Nicolas Meneveau (1), Evelyne Racadot (2), Vincent Descotes-Genon (1), Romain Chopard (1), Marie-France Seronde (1), Sebastien Janin (1)

(1) CHU de Besançon, Cardiologie, Besançon, France - (2) EFS Bourgogne-Franche Comté, Besançon, France

Background: Recombinant factor VIIa (rFVIIa) may be used to reverse the anticoagulant effect of fondaparinux. We report a single centre experience in 8 patients with severe bleeding.

Methods: Patients pretreated with fondaparinux, with life-threatening bleeding were treated with 90µg/kg rFVIIa. Life-threatening bleeding was defined as TIMI 3 bleeding or a drop in hemoglobin > 5g or hemodynamic shock and elevated antiXa activity. Endpoints were (1) death (2) persistent bleeding (clinical or continued drop of hemoglobin) (3) uncontrolled hemod-

© Elsevier Masson SAS. All rights reserved.